BRUKINSA Data Presented at ASCO Highlights Distinctive Clinical Efficacy for CLL and SLL Treatment
A global oncology company today announced the presentation of new analyses for BRUKINSA® (zanubrutinib) at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31 to…
Empowering Women in Clinical Trials: 5 Inspiring Quotes to Drive Change
Clinical Trials Day is globally recognized on May 20, and this year, the Walgreens Clinical Trials team celebrated with a special event dedicated to women’s health. Appropriately, May is National…
Merck to Present Latest Cancer Research Advancements at ASCO 2024
First-in-human data for the potential first-in-class anti-CEACAM5 ADC with topoisomerase 1 inhibitor payload, M9140, in the treatment of metastatic colorectal cancer to be featured in an oral presentation. Phase I…
Lilly Invests $9B in Indiana Site to Boost Tirzepatide and Pipeline API Production
Eli Lilly and Company announced today a significant increase in investment for its Lebanon, Indiana, manufacturing site. The company has committed an additional $5.3 billion, bringing the total investment to…
Astellas and YASKAWA Partner to Forge a Cutting-Edge Cell Therapy Ecosystem Blending Pharmaceutical and Robotics Expertise
Today, Astellas announced the signing of a memorandum of understanding with YASKAWA Electric Corporation (YASKAWA), marking the beginning of discussions toward creating an innovative cell therapy ecosystem. This collaboration aims…
Nature Communications: CSL, Arcturus COVID-19 Vaccine Efficacy Data Published
CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) have announced the publication of groundbreaking findings in Nature Communications, revealing the results from a comprehensive phase 1/2/3a/3b study investigating the safety,…
Aetna Grants $400K for Roanoke, VA Residential Facility Helping Moms with Substance Use Disorder
Aetna Better Health of Virginia, a CVS Health® company, has pledged $400,000 to Restoration Housing to facilitate the acquisition of a property in Roanoke, Virginia. This property will be utilized…
Empowering Schizophrenia Community: Live Your PosSCZible Campaign with Bristol Myers Squibb and Taye Diggs
Bristol Myers Squibb (NYSE: BMY) has unveiled the Live Your PosSCZible campaign, a nationwide initiative developed in collaboration with the schizophrenia community. The campaign aims to amplify firsthand experiences and…
Live Your PosSCZible Campaign: Bristol Myers Squibb, Taye Diggs, and Schizophrenia Community Unite to Empower Individuals with Schizophrenia
Bristol Myers Squibb (NYSE: BMY) has unveiled the Live Your PosSCZible campaign, a nationwide initiative in collaboration with the schizophrenia community. The campaign aims to amplify personal experiences, offering educational…
AstraZeneca Aims for $80 Billion in Revenue by 2030 with Continued Growth Beyond
Today, AstraZeneca unveiled its ambitious target to achieve $80 billion in Total Revenue by 2030, a significant increase from the $45.8 billion reported in 2023. This expansion will be fueled…
AstraZeneca Announces $1.5 Billion Facility for Antibody Drug Conjugates (ADCs) Manufacturing in Singapore
AstraZeneca to Establish $1.5 Billion Antibody Drug Conjugates (ADCs) Manufacturing Facility in Singapore AstraZeneca plans to build a $1.5 billion manufacturing facility in Singapore, aimed at enhancing the global supply…
FDA Grants Breakthrough Status to Roche’s Inavolisib for Advanced HR+, HER2- Breast Cancer
Roche announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with palbociclib (Ibrance®) and fulvestrant. This…